Villanueva, Vicente http://orcid.org/0000-0003-2080-8042
Laloyaux, Cédric
D’Souza, Wendyl http://orcid.org/0000-0002-1750-5131
Faught, Edward
Klein, Pavel
Reuber, Markus
Rosenow, Felix
Salas-Puig, Javier
Insuga, Victor Soto
Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Szaflarski, Jerzy P. http://orcid.org/0000-0002-5936-6627
Chinn, Chris
Daniels, Tony
Floricel, Florin
Friesen, David
Sendersky, Veronica
Besson, Hervé
Steinhoff, Bernhard J. http://orcid.org/0000-0001-5995-5862
Funding for this research was provided by:
UCB Pharma
Article History
Accepted: 26 July 2023
First Online: 9 September 2023
Declarations
:
: This study was funded by UCB Pharma. The sponsor was involved in the design of the study, the collection, analysis, and interpretation of data, and in the decision to publish the manuscript.
: VV has served as a consultant or on an advisory board, for Arvelle Therapeutics, Bial, Eisai, Esteve, GW Pharmaceuticals, Novartis, and UCB Pharma; has received research grants from Bial, Eisai, and UCB Pharma; and has received speaker’s honoraria from Bial, Eisai, Esteve, GW Pharmaceuticals, Novartis, and UCB Pharma. WDS has a salary that is part-funded by The University of Melbourne; he has received travel, investigator-initiated, scientific advisory board, and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel, and speaker honoraria from Eisai Australia & Global; advisory board honoraria from LivaNova and Tilray; educational grants from Novartis, Pfizer, and Sanofi-Synthélabo; educational, travel, and fellowship grants from GSK Neurology Australia; and honoraria from ScieGen Pharmaceuticals; he has an equity interest in the device company Epiminder. EF has received research grants from Janssen and UCB Pharma, and has served as a consultant for Aucta, Biogen, Eisai, LivaNova, Neurelis, SK Life Science, and Trevena. PK has served as a consultant for Abbott, Arvelle Therapeutics, Neurelis, and SK Life Science; as a consultant, advisory board member, and speaker for Aquestive, Eisai, Sunovion, and UCB Pharma; is a member of the medical advisory board of Stratus and the scientific advisory board of OB Pharma; is the CEO of PrevEp; and has received research support from CURE and Department of Defense/Lundbeck. MR receives payment from Elsevier as editor-in-chief of <i>Seizure</i>; and has received research grants and speaker’s fees from Eisai, LivaNova, and UCB Pharma. FR reports personal fees from Angelini Pharma, Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals; personal fees and other from Novartis; personal fees and grants from UCB Pharma; and grants from the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt, Deutsche Forschungsgemeinschaft, the European Union, and the State of Hessen outside of the submitted work. JSP has received grants from Bial and UCB Pharma; and reports personal fees from Bial, Eisai, Esteve, Sanofi, and UCB Pharma outside of the submitted work. VSI has received speaker honoraria from Bial, Eisai, and UCB Pharma. AS reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW/Jazz Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma/Zogenix, and UNEEG Medical, outside of the submitted work. JPS has received research funding from Biogen, Department of Defense, Eisai, GW Pharmaceuticals companies, National Institutes of Health, National Science Foundation, NeuroPace, Serina Therapeutics, Shor Foundation for Epilepsy Research, State of Alabama General Funds, and UCB Pharma; has served as a consultant or advisory board member for Elite Medical Experts, GW Pharmaceuticals companies, LivaNova, Lundbeck, Medical Association of the State of Alabama, NeuroPace, Serina Therapeutics, SK Life Science, and UCB Pharma; has served as an investigator on GW Research Ltd trials; and is an editorial board member for <i>Epilepsy & Behavior, Epilepsy & Behavior Reports</i> (editor-in-chief), <i>Folia Medica Copernicana, Journal of Epileptology</i> (associate editor), and <i>Journal of Medical Science</i>. HB, CC, TD, FF, CL, and VS are employees of UCB Pharma. DF is an independent contractor working for UCB Pharma. BJS has received speaker honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, and UCB Pharma; and has served as a consultant for Arvelle Therapeutics, B. Braun, Bial, Desitin, Eisai, GW Pharmaceuticals, and UCB Pharma. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
: Data from non-interventional studies are outside of UCB Pharma’s data sharing policy and are unavailable for sharing.
: No ethics committee approval was required for the EXPERIENCE database given that the database consisted of Health Insurance Portability and Accountability Act and General Data Protection Regulation (GDPR) compliant anonymised data. The Australian (AUS) and United States of America (USA) cohorts required ethics approval to release their data for inclusion in the EXPERIENCE database. Each non-interventional study that was included in EXPERIENCE received appropriate ethics and/or scientific review board approval as part of the initial study proposal at each institution.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors made substantial contributions to study conception/design, or acquisition/analysis/interpretation of data; and drafting of the manuscript, or revising it critically for important intellectual content. All authors read and provided final approval of the manuscript.